Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

March 13, 2024

https://www.globenewswire.com/news-release/2024/03/13/2845779/0/en/Phio-Pharmaceuticals-Announces-Addition-of-Clinical-Trial-Sites-at-Banner-MD-Anderson-Cancer-Center-The-George-Washington-University-and-Integrity-Research.html

MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the addition of three clinical trial sites for its Phase 1b study of PH-762:

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.